Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
ConditionAdolescent Asthma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJiangsu HengRui Medicine Co., Ltd.
About this trial
Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis
Eligibility criteria
Qualifiers
Age 18-75 years old (including boundary values), male and female.
Female subjects weigh ≥45 kg and male subjects weigh ≥50 kg.
HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB.
The expected survival is greater than 12 months.
Disqualifiers
Patients with pulmonary hypertension or chronic obstructive pulmonary disease (COPD) or asthma as determined by the investigators were the primary diagnosis were screened.
An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc.
Have psoriasis or lichen planus.
Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis.
Trial design
Treatments tested in this trial
- RSS0343 Tabella
Treatment groups
252 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov